QRxPharma inks deal with Actavis for MoxDuo IR commercialisation in US
This article was originally published in Scrip
Executive Summary
QRxPharma has signed a binding letter of intent with Actavis for Actavis Group's US subsidiary to commercialise its acute pain candidate, MoxDuo IR, in the US.